TNFRSF10A and cancer: Agonistic human or mouse monoclonal antibodies (mAbs) that specifically activate DR4 or DR5 without triggering DcR1 and DcR2 have been demonstrated as potential candidates for cancer therapy [2,21,22,23,24,25,26,27,28].